CD8A and neoplasm: Speaking of TNBC, Baleeiro et al. developed a “personalized viro-immunotherapy platform” that combined tumor-selective oncolytic vaccinia virus with separately delivered neoantigen peptides and provided promising results in a preclinical model of TNBC, eliciting tumor-specific immune response and changing the TME to attract and maintain mature cross-presenting CD8α + DCs and effector T-cells, which resulted in tumor growth inhibition and improved survival [237].